MetaCap

4D Molecular Therapeutics Inc. (FDMT)

NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

10.23-0.49 (-4.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FDMT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$576.76M
EPS (TTM)
-$2.70
52-week range
6.96 – 16.93
Day range
10.11 – 10.94
Volume / Avg
690.94K / 967.00K
Beta
—

52-week range

$6.96$16.93

FDMT stock today

4D Molecular Therapeutics (FDMT) closed at $10.23 on Nov 20, down 4.57% (-$0.49), versus the S&P 500's 3.70% decline. Shares are 39.6% below their 52-week high of $16.93, set on Aug 19, 2026 and 47.0% above the 52-week low of $6.96, in the middle of the past year's range. FDMT is up 36.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.6%.

4D Molecular Therapeutics has posted a net loss over the last twelve months (EPS of -$2.70), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About 4D Molecular Therapeutics

Company profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. David H. Kirn M.D.
Headquarters
EmeryVille, CA
Employees
196
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, 4D Molecular Therapeutics generated $85.2 million in revenue, up 230194.6% from fiscal 2024. 4D Molecular Therapeutics reported a net loss of $140.1 million, compared with a loss of $160.9 million a year earlier. Operating margin was -187.2%.

4D Molecular Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$85.21M$37.00K$20.72M$3.13M$18.04M
Growth+230194.59%-99.82%+562.29%-82.65%+32.52%
Net income$-140.11M$-160.87M$-100.84M$-107.49M$-71.32M
EPS (diluted)$-2.42$-2.98$-2.58$-3.32$-2.57

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$28.09+174.58%

  • Strong buy 2
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $37.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.08 vs $-1.04
Surprise
-3.85%

FDMT news

All FDMT news

4D Molecular Therapeutics peers

Health Care sector
FDMT peer companies
CompanyPrice% ChgMarket capCompare
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs FDMT
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs FDMT
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs FDMT
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs FDMT
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs FDMT
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs FDMT
VALNValneva SE ADR5.16-3.82%$490.86Mvs FDMT
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs FDMT

Indexes, lists and sector

4D Molecular Therapeutics stock FAQ

What is 4D Molecular Therapeutics's stock price today?

FDMT last traded at $10.23 as of Nov 20, 4:00 PM EST, down 4.57% on the day. Prices are delayed at least 15 minutes.

Who is 4D Molecular Therapeutics's CEO?

Dr. David H. Kirn M.D. is the chief executive officer of 4D Molecular Therapeutics Inc., which has about 196 employees.

What is the FDMT 52-week high?

The 52-week high for FDMT is $16.93 and the 52-week low is $6.96. The stock is currently 39.6% below its high.

Compare FDMT